← All trials
NCT02691078
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2016
- Primary completion
- Jan 31, 2018
- Completion date
- Jan 10, 2018
- First posted
- Feb 25, 2016
- Last posted
- Sep 1, 2023
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Latin American Cooperative Oncology GroupLead sponsor
- Instituto do Cérebro do Rio Grande do Sul - InsCerCollaborator
- Latin American Cooperative Oncology GroupStudy director
- Latin American Cooperative Oncology GroupOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.